thalidomide has been researched along with Leukemia, Myelomonocytic, Chronic in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 7.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 6.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 3.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 2.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sekeres, MA | 1 |
| Othus, M | 1 |
| List, AF | 1 |
| Odenike, O | 1 |
| Stone, RM | 1 |
| Gore, SD | 1 |
| Litzow, MR | 1 |
| Buckstein, R | 2 |
| Fang, M | 1 |
| Roulston, D | 1 |
| Bloomfield, CD | 1 |
| Moseley, A | 1 |
| Nazha, A | 1 |
| Zhang, Y | 1 |
| Velasco, MR | 1 |
| Gaur, R | 1 |
| Atallah, E | 1 |
| Attar, EC | 1 |
| Cook, EK | 1 |
| Cull, AH | 1 |
| Rauh, MJ | 1 |
| Appelbaum, FR | 1 |
| Erba, HP | 1 |
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Kerbel, R | 1 |
| Cheung, M | 1 |
| Shaked, Y | 1 |
| Chodirker, L | 1 |
| Lee, CR | 1 |
| Lenis, M | 1 |
| Davidson, C | 1 |
| Cussen, MA | 1 |
| Reis, M | 1 |
| Chesney, A | 1 |
| Zhang, L | 1 |
| Mamedov, A | 1 |
| Wells, RA | 1 |
| Kenealy, M | 1 |
| Patton, N | 1 |
| Filshie, R | 1 |
| Nicol, A | 1 |
| Ho, SJ | 1 |
| Hertzberg, M | 1 |
| Mills, T | 1 |
| Prosser, I | 1 |
| Link, E | 1 |
| Cowan, L | 1 |
| Zannino, D | 1 |
| Seymour, JF | 1 |
| Steensma, DP | 1 |
| Tefferi, A | 1 |
| Strupp, C | 1 |
| Germing, U | 1 |
| Aivado, M | 1 |
| Misgeld, E | 1 |
| Haas, R | 1 |
| Gattermann, N | 1 |
| Zorat, F | 1 |
| Pozzato, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"[NCT00744536] | Phase 2 | 20 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Mo | 2007 |
Thalidomide in myelodysplastic syndromes.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Abe | 2002 |
3 trials available for thalidomide and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocyt | 2014 |
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Ma | 2017 |
1 other study available for thalidomide and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Thalidomide for the treatment of patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transf | 2002 |